Clinical implications of immunoreactivity of thymidylate synthase and dihydropyrimidine dehydrogenase in gastric cancer treated with oral fluoropyrimidine (S-1). Study Group of S-1 for Gastric Cancer.

International journal of oncology

Volumn 17, Issue 4, 2000, Pages 653-658

  Miyamoto, S ^a   Boku, N ^a   Ohtsu, A ^a   Yoshida, S ^a   Ochiai, A ^a   Okabe, H ^a   Fukushima, M ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; DIHYDROPYRIMIDINE DEHYDROGENASE; OXIDOREDUCTASE; OXONIC ACID; PYRIDINE DERIVATIVE; S 1 (COMBINATION); TEGAFUR; THYMIDYLATE SYNTHASE;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL TRIAL; DRUG COMBINATION; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; STOMACH TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODY SPECIFICITY; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG COMBINATIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; OXIDOREDUCTASES; OXONIC ACID; PYRIDINES; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TEGAFUR; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 0034297095     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.17.4.653     Document Type: Article

References (0)